Savara inc（SVRA.US Overview）

US StockHealthcare

No presentation for SVRA

Overview AI Analysis AI Earnings Summary Earnings Event Stats Financials Financial Forecast Stock Sentimental Institutions

SVRA AI Insights

SVRA Overall Performance

SVRA AI Analysis & Strategy

SVRA Recent Performance

3.29%

Savara inc

2.16%

Avg of Sector

0.28%

S&P500

SVRA PowerScanner

SVRA Key Information

SVRA Valuation Metrics

SVRA Earnings Table

SVRA Profile

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.